GlassScriptPhysician profile
Francis E Heidt
NPI 1497796999
$1,765.13
in general payments reported to CMS, 2019-2025
27 companies · $532 in 2025
The $532 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $410 · 2020: $50.16 · 2022: $67.67 · 2023: $257 · 2024: $447 · 2025: $532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,236.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $290.29 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Exact Sciences Corporation | $272.79 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $221.79 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Pfizer INC. | $158.78 | 2019-2025 | |
| Lilly USA, LLC | $101.28 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $84.56 | 2019-2025 | |
| Daiichi Sankyo INC. | $76.86 | 2019-2024 | Injectafer |
| Amgen INC. | $75.12 | 2019-2024 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $69.09 | 2019 | |
| Glaxosmithkline, LLC. | $49.56 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Dexcom, INC. | $43.28 | 2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $37.93 | 2023-2024 | Gvoke Hypopen |
| Amarin Pharma, INC. | $31.90 | 2019-2020 | |
| Eisai INC. | $31.77 | 2025 | |
| Novartis Pharmaceuticals Corporation | $29.18 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $26.00 | 2020-2024 | Veozah |
| Edwards Lifesciences Corporation | $25.53 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.16 | 2025 | Jardiance |
| Esperion Therapeutics, INC. | $16.63 | 2025 | Nexletol |
| Phathom Pharmaceuticals, INC. | $15.00 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $13.71 | 2022 | |
| Allergan, INC. | $13.04 | 2019 | |
| Ironshore Pharmaceuticals INC. | $12.99 | 2019 | |
| Promius Pharma LLC | $12.59 | 2019 | |
| Dynavax Technologies Corporation | $12.57 | 2024 | Heplisav-B |
| Sanofi-Aventis U.S. LLC | $11.48 | 2020 | |
| Merck Sharp & Dohme LLC | $11.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francis Heidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.